| 000 | 01777 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250517113030.0 | ||
| 264 | 0 | _c20170324 | |
| 008 | 201703s 0 0 eng d | ||
| 022 | _a1096-0295 | ||
| 024 | 7 |
_a10.1016/j.yrtph.2016.08.009 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aSengupta, Pinaki | |
| 245 | 0 | 0 |
_aSafety profiling of pioglitazone and telmisartan combination by sub-chronic toxicity study in rat. _h[electronic resource] |
| 260 |
_bRegulatory toxicology and pharmacology : RTP _cNov 2016 |
||
| 300 |
_a155-161 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdministration, Oral |
| 650 | 0 | 4 |
_aAngiotensin II Type 1 Receptor Blockers _xadministration & dosage |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xadministration & dosage |
| 650 | 0 | 4 |
_aBenzimidazoles _xadministration & dosage |
| 650 | 0 | 4 |
_aBenzoates _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHypoglycemic Agents _xadministration & dosage |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPioglitazone |
| 650 | 0 | 4 | _aPolypharmacy |
| 650 | 0 | 4 | _aRats, Wistar |
| 650 | 0 | 4 | _aRisk Assessment |
| 650 | 0 | 4 | _aTelmisartan |
| 650 | 0 | 4 |
_aThiazolidinediones _xadministration & dosage |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aToxicity Tests, Subchronic _xmethods |
| 700 | 1 | _aDas, Arindam | |
| 700 | 1 | _aIbrahim, Fuzianna | |
| 700 | 1 | _aMandal, Uttam Kumar | |
| 700 | 1 | _aChatterjee, Bappaditya | |
| 700 | 1 | _aMahmood, Syed | |
| 700 | 1 | _aDas, Sreemoy Kanti | |
| 700 | 1 | _aKifayatullah, Muhammad | |
| 773 | 0 |
_tRegulatory toxicology and pharmacology : RTP _gvol. 81 _gp. 155-161 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.yrtph.2016.08.009 _zAvailable from publisher's website |
| 999 |
_c26367600 _d26367600 |
||